{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:36:57Z","timestamp":1790800617682,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00344","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:48:42Z","timestamp":1583236122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions"],"prefix":"10.3389","volume":"11","author":[{"given":"Tanja","family":"Fetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Guel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Braegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","article-title":"The classification and diagnosis of cutaneous lupus erythematosus.","author":"Kuhn","year":"2014","journal-title":"J Autoimmun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/exd.12708","article-title":"Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus.","volume":"24","author":"Kunz","year":"2015","journal-title":"Exp Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.jisp.2016.09.002","article-title":"Genomic investigation of lupus in the skin.","volume":"18","author":"Sinha","year":"2017","journal-title":"J Investig Dermatol Symp Proc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.21658","article-title":"Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation.","volume":"54","author":"Kuhn","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00035","article-title":"Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE.","volume":"7","author":"Mahajan","year":"2016","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2013.04.020","article-title":"Systemic involvement in TREX1-associated familial chilblain lupus.","volume":"69","author":"G\u00fcnther","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01636","article-title":"Nucleic acid immunity in the pathogenesis of cutaneous lupus erythematosus.","volume":"10","author":"G\u00fcnther","year":"2019","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jid.2017.03.018","article-title":"Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus.","volume":"137","author":"Scholtissek","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1523-1747.2002.19515.x","article-title":"Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases.","volume":"119","author":"Wollenberg","year":"2002","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.jid.2019.02.035","article-title":"Delineating the healthy human skin UV response and early induction of interferon pathway in cutaneous lupus erythematosus.","volume":"139","author":"Katayama","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01028","article-title":"Sources of pathogenic nucleic acids in systemic lupus erythematosus.","volume":"10","author":"Mustelin","year":"2019","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jid.2018.02.034","article-title":"Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis.","volume":"138","author":"Lauffer","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5114\/ada.2018.75242","article-title":"Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.","volume":"35","author":"Samotij","year":"2018","journal-title":"Postepy Dermatol Alergol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijwd.2018.01.002","article-title":"Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: a qualitative study.","volume":"4","author":"Ogunsanya","year":"2018","journal-title":"Int J Womens Dermatol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17787.1","article-title":"Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.","volume":"8","author":"Chen","year":"2019","journal-title":"F1000Research"},{"key":"B17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2019.1608821","article-title":"Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.","volume":"15","author":"Kubo","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.","volume":"205","author":"Wenzel","year":"2005","journal-title":"J Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket.","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem Biol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02841869109092414","article-title":"Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment.","volume":"30","author":"R\u00f6nnblom","year":"1991","journal-title":"Acta Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1600-0560.2007.00715.x","article-title":"Lupus-like reaction to interferon at the injection site: report of five cases.","volume":"34","author":"Arrue","year":"2007","journal-title":"J Cutan Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-015-0550-0","article-title":"Lupus erythematosus revisited.","volume":"38","author":"Kuhn","year":"2016","journal-title":"Semin Immunopathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE).","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a Phase I, multicentre, double-blind randomised study.","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and Type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/exd.12957","article-title":"Update on the role of plasmacytoid dendritic cells in inflammatory\/autoimmune skin diseases.","volume":"25","author":"Saadeh","year":"2016","journal-title":"Exp Dermatol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.6259","article-title":"BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous LE.","volume":"76","author":"Furie","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","article-title":"A role for JAK2 mutations in myeloproliferative diseases.","volume":"59","author":"Morgan","year":"2008","journal-title":"Annu Rev Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.","volume":"22","author":"Pardanani","year":"2008","journal-title":"Leukemia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1517\/14656566.2014.923404","article-title":"Efficacy of ruxolitinib for myelofibrosis.","volume":"15","author":"Santos","year":"2014","journal-title":"Expert Opin Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases.","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease.","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: clinical overview and molecular basis.","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease.","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib.","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review.","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 Inhibitor ruxolitinib controls a case of chilblain lupus erythematosus.","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/annrheumdis-2018-214037","article-title":"Efficacy of JAK1\/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.","volume":"78","author":"Briand","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","article-title":"Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation.","volume":"155","author":"Zimmermann","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING.","volume":"76","author":"K\u00f6nig","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2340\/00015555-2960","article-title":"Tofacitinib represses the Janus kinase-signal transducer and activators of transcription signalling pathway in keratinocytes.","volume":"98","author":"Srivastava","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a Phase II randomized trial of topical R333 for discoid lupus erythematosus.","volume":"178","author":"Presto","year":"2018","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ajpath.2013.04.027","article-title":"An ENU mutagenesis-derived mouse model with a dominant JAK1 mutation resembling phenotypes of systemic autoimmune disease.","volume":"183","author":"Sabrautzki","year":"2013","journal-title":"Am J Pathol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus."},{"key":"B48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, Phase 2 trial.","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a Phase 2 randomized clinical trial.","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model.","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction.","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B.","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors \u2013 a double blind, placebo, and active controlled pilot study.","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream.","volume":"145","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:48:45Z","timestamp":1583236125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2020.00344"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00344","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"article-number":"344"}}